Results 151 to 160 of about 48,174 (231)

QALYs or short straws

BMJ, 1986
openaire   +5 more sources

Cost-Effectiveness Analysis of Ivonescimab Plus Chemotherapy versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer in China Based on the HARMONi-6 Trial. [PDF]

Risk Manag Healthc Policy
Xuan F, Huang M, Yang Y, Bian H.
europepmc   +1 more source

Imaging-guided treatment strategy compared to standard care in at-risk individuals for rheumatoid arthritis: a cost-utility analysis. [PDF]

BMJ Open
Bour S, Van Mulligen E, Goossens L, de Jong PHP, van der Helm-van Mil A, Rutten-van Molken M.   +5 more
europepmc   +1 more source

Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial. [PDF]

Front Public Health
Feng R, Liang P, Wang Y, Li D, Jia H, Zheng Y, Huo L, Lv Q.   +7 more
europepmc   +1 more source

Cost-effectiveness of early versus delayed disease-modifying antirheumatic drugs for psoriatic arthritis. [PDF]

Lancet Reg Health Am
Hundal S, Cappelli J, Haidar S, Osman M, Kaouache M, Rahme E, Goldberg SR, Gladman DD, Ringuet J, Muntyanu A, Tsoukas A, Netchiporouk E.   +11 more
europepmc   +1 more source

Modeling the cost-effectiveness of introducing donation after controlled circulatory death for heart transplantation in France. [PDF]

Transpl Int
Atfeh J, Guerre P, Guihaire J, Sebbag L, Pozzi M, Huot L.   +5 more
europepmc   +1 more source

Reply to Brunner, M. Comment on "Värendh et al. A Cost-Effectiveness Analysis of the Sentio Bone Conduction Hearing Implant System in the Australian Healthcare Setting. <i>J. Mark. Access Health Policy</i> 2026, <i>14</i>, 8". [PDF]

J Mark Access Health Policy
Värendh M, Haggren I, Lagerkvist H, Åberg Håkansson M, Hjelmgren J.   +4 more
europepmc   +1 more source